DANA-FARBER CANCER INSTITUTE

Desai Sethi Urology Institute researchers found that prostate cancer patients with the adrenal-permissive HSD3B1 allele had better survival outcomes when treated with ADT plus enzalutamide or ADT plus nonsteroidal antiandrogen, reversing poor genetic outcomes.

Diagnostic errors affect 1 in 20 adults annually, with cancer being the most severe misdiagnosis. These errors impact clinical trial participation, where late-stage patients may face increased risks. Solutions include centralised review teams, improved care coordination, and establishing Diagnostic Safety Centers of Excellence. Drug safety/pharmacovigilance (DSPV) plays a crucial role in safeguarding patient safety and ensuring accurate reporting to regulatory agencies.

Kura Oncology appoints Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles brings over 25 years of oncology drug development experience and leadership. He is currently a Senior Advisor at Frazier Healthcare Partners and has held senior roles at ImmunoGen, Flatiron Health, Unum Therapeutics, Takeda/Millennium, and Genzyme Corporation. Dr. Vasconcelles expressed enthusiasm for Kura's precision oncology approach and its menin inhibitor program for acute leukemias.

Final results from the CABINET phase III trial show cabozantinib significantly improves median progression-free survival in previously treated advanced neuroendocrine tumors, with no new safety concerns. The data was presented at ESMO 2024 and published in the New England Journal of Medicine.

Paolo Tarantino discusses how advancements in HER2-positive early-stage breast cancer treatment, including anthracycline-based regimens, non-anthracycline alternatives, and biomarker integration, are leading to more personalized medicine. Trastuzumab, pertuzumab, TKIs, and trastuzumab emtansine are central to these advancements, aiming to optimize treatment and minimize adverse effects. The HER2DX assay and imaging biomarkers like PET scans and MRI are refining treatment decisions, while neoadjuvant treatment strategies allow for tailored post-treatment care.

An antibody-drug conjugate, T-DXd, shows 'impressive' activity against HER2-positive breast cancer with brain metastases, according to the DESTINY-Breast 12 trial. Median progression-free survival was 17.3 months for patients with brain metastases, with 61.6% achieving 12-month PFS and 71% showing intracranial objective response. Side effects were consistent with previous studies, emphasizing the need for monitoring.

FDA granted accelerated approval to epcoritamab-bysp (Epkinly) for relapsed/refractory follicular lymphoma, based on EPCORE NHL-1 trial results. Dr. Jennifer Crombie discusses the approval's significance and future of FL treatment.

The CABINET phase III trial showed cabozantinib significantly improved median progression-free survival (PFS) in previously treated neuroendocrine tumors (NETs), with 13.8 months for pNET and 8.4 months for epNET compared to 4.4 and 3.9 months for placebo, respectively. The results, presented at ESMO 2024 and published in NEJM, support cabozantinib as a potential new standard of care for advanced NET patients.

Final results from the CABINET phase III trial show cabozantinib significantly improves median progression-free survival (PFS) in previously treated advanced neuroendocrine tumors (pNET and epNET), with PFS of 13.8 months vs 4.4 months for pNET and 8.4 months vs 3.9 months for epNET. The study also demonstrated benefits across all clinical subgroups and a safety profile consistent with previous findings, leading to an early unblinding of the trial and a supplemental new drug application for cabozantinib.